Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 51.95 USD 1.94% Market Closed
Market Cap: 105.8B USD

During the last 3 months Bristol-Myers Squibb Co insiders have not bought any shares, and have not sold any shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Sep 2, 2025 by Elkins David V , who sold 2.7m USD worth of BMY shares.

Last Transactions:
Elkins David V
$-2.7m
Short Bartie Wendy
$-16.7k
Hickey Benjamin
$-3.7k
Hirawat Samit
$+202.2k
Boerner Christopher S.
$+110.1k
Hirawat Samit
$+100k
Holzer Phil M
$-38.9k
Hirawat Samit
$+100.1k
Boerner Christopher S.
$+99.6k
Boerner Christopher S.
$+150k
Samuels Theodore R. Ii
$+423.4k
Powell Ann
$-1.1m
Plenge Robert M
$-44.8k
Vessey Rupert
$-3.4m
Powell Ann
$-835.3k
Caforio Giovanni
$-17.9m
Powell Ann
$-1.3m
Vessey Rupert
$-3.6m
Caforio Giovanni
$-1.7m
Caforio Giovanni
$-3.6m
Powell Ann
$-1.8m
Elkins David V
$-2.1m
Caforio Giovanni
$-2.2m
Leung Sandra
$-4.9m
Caforio Giovanni
$-1.8m
Vessey Rupert
$-2.2m
Santiago Karen Murphy
$-455.1k
Boerner Christopher S.
$-2m
Caforio Giovanni
$-2m
Vessey Rupert
$-384.2k
Von Autenried Paul
$-987.7k
Von Autenried Paul
$-886.1k
View All Transactions

During the last 3 months Bristol-Myers Squibb Co insiders have not bought any shares, and have not sold any shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Sep 2, 2025 by Elkins David V , who sold 2.7m USD worth of BMY shares.

Sold
0-3
months
0 USD
0
3-6
months
2.7m USD
2
6-9
months
3.7k USD
1
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
0
0 USD
6-9
months
1
202.2k USD
9-12
months
2
210.1k USD

Bristol-Myers Squibb Co
Insider Trading Chart

Bristol-Myers Squibb Co
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Bristol-Myers Squibb Co
Last Insider Transactions

Global
Insiders Monitor

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
72.37 USD
Undervaluation 28%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top